Per the terms of the agreement, Novavax will receive an upfront payment of $30 million from Pfizer and is eligible to earn up to $500 million in potential development and commercial milestone payments ...
Novavax NVAX announced a non-exclusive license agreement with Pfizer PFE, granting the latter access to its proprietary Matrix-M adjuvant technology for use in up to two disease areas. The ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results